Last reviewed · How we verify
7vPnC
7vPnC is a vaccine that protects against meningococcal disease caused by serogroups B and Y.
7vPnC is a vaccine that protects against meningococcal disease caused by serogroups B and Y. Used for Prevention of meningococcal disease caused by serogroups B and Y in individuals 10 through 25 years of age.
At a glance
| Generic name | 7vPnC |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
7vPnC is a conjugate vaccine that combines the meningococcal serogroup B and Y capsular polysaccharides with a diphtheria toxoid carrier protein. This conjugation enhances the immune response and provides protection against meningococcal disease caused by these serogroups.
Approved indications
- Prevention of meningococcal disease caused by serogroups B and Y in individuals 10 through 25 years of age
Common side effects
- Pain, redness, swelling, or bruising at the injection site
- Fatigue
- Headache
Key clinical trials
- Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan (PHASE3)
- Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants (PHASE3)
- Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
- A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China (PHASE3)
- Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization (PHASE3)
- A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. (PHASE4)
- Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants (PHASE3)
- Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 7vPnC CI brief — competitive landscape report
- 7vPnC updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI